British Journal of Anaesthesia, Vol 78, Issue 6 724-730, Copyright © 1997 by The Board of Management and Trustees of the British Journal of Anaesthesia
V. Patella, A. Ciccarelli, B. Lamparter-Schummert, A. de Paulis, M. Adt and G. Marone
To investigate the mechanisms of anaphylactoid reactions to protamine, we
have examined the in vitro effects of increasing concentrations of
protamine (10(-6)-3 x 10(-4) mol litre-1) on the release of preformed
(histamine and tryptase) and de novo synthesized (peptide leukotriene C4
(LTC4) or prostaglandin D2 (PGD2)) mediators from human basophils and mast
cells isolated from lung parenchyma, heart, skin and synovial tissues.
Protamine 10(-6)-3 x 10(-4) mol litre-1 induced release of histamine, but
not de novo synthesis of LTC4 from basophils. At concentrations from 10(-5)
to 3 x 10(-4) mol litre-1 it induced histamine release from human heart
(mean 6.5 (SEM 1.5)%), skin (17.7 (4.1)%) and to a lesser extent from
synovial mast cells, but not from lung mast cells. Protamine also caused
the release of tryptase from heart mast cells (12.8 (3.2) micrograms/10(7)
cells), but did not induce de novo synthesis of LTC4 and PGD2 from lung and
skin mast cells. In these experiments cross-linking of IgE by anti-IgE
caused release of LTC4 or PGD2 from human basophils or mast cells. These
results demonstrate that protamine acted as an incomplete secretagogue,
causing the release of preformed mediators from human basophils and mast
cells.
LABORATORY INVESTIGATIONS
Heterogeneous effects of protamine on human mast cells and basophils
Division of Clinical Immunology and Allergy, University of Naples Federico II, School of Medicine, Via S. Pansini 5, 80131 Napoli, Italy; Department of Anaesthesiology, German Heart Institute Berlin, Berlin, Germany
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
C. M. Dyke, N. G. Smedira, A. Koster, S. Aronson, H. L. McCarthy II, R. Kirshner, A. M. Lincoff, and B. D. Spiess A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: The EVOLUTION-ON study J. Thorac. Cardiovasc. Surg., March 1, 2006; 131(3): 533 - 539. [Abstract] [Full Text] [PDF] |
||||
